Obesity
Obesity is a global epidemic, impacting 100 million people in the U.S. and 800 million worldwide—with the latter figure projected to reach 1.5 billion by 2030.
The most effective approaches to weight loss work by controlling the satiety-hormone axis, specifically elevating circulating satiety hormones. This can be reached through bariatric surgery or pharmacologically, such as with GLP-1 therapies. While GLP-1 drugs have achieved unprecedented weight loss for many patients, they rely on sustained circulating drug levels to maintain their effect – which can produce gastrointestinal and other treatment-limiting effects, particularly as doses are escalated.
Our portfolio of obesity therapies may offer an alternative and/or complementary approach intended to provide patients with a more affordable and sustainable path forward.